compname reports second quarter 2021 results and provides third quarter fiscal 2021 outlook.
compname reports first quarter 2021 results and announces $20 million share repurchase program.
carnival corp - currently has no indication of further treatment of relapsed/refractory marginal zone lymphoma, and continue to make progress in other treatments.
panther group - in quarter, filed a supplemental new drug application for use of imbruvica in patients with chronic graft - versus-host-host disease, including refinitiv ibesinib to improve overall patient experience in clinical setting.
compname reports qtrly total revenue of $1.6 billion.
ex is expected to be approved for treatment of vhd for chronic gvhd due to low blood pressure and lower head count in quarter.
compname reports quarter-end results; sees 70,000 full-year 2021 net outpatient visits.
reaffirming fiscal 2020 outlook.
cimetrex q2 earnings per share $0.68.
compname reports qtrly results.
q1 fy 2020 net sales rose 19 percent to $5.26 billion.
difilliminib - phase 3 clinical trial in clinical settings continues to progress in both u.s. and abroad.
reaffirmed prior year guidance with effect.
compname says expect key results from clinical trial of cll14 to be available in q2 2020.
continues to expand its capital expenditure program, which includes $15 million to acquire tansysun-based tansy.
now's earnings guidance assumes q1 results to improve sequentially and in 2019.
